Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor
Navigation Menu

Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor

Infusion reactions and effectiveness of front-line obinutuzumab and chlorambucil for chronic lymphocytic leukemia

Infusion reactions and effectiveness of front-line obinutuzumab and chlorambucil for chronic lymphocytic leukemia

Posted by on May 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate infusion reactions and the effectiveness of the combination of obinutuzumab (Gazyva) and chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL).  This study concluded that first dose infusion reactions with obinutuzumab can be reduced by using chlorambucil first and by using a very...

Read More

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Investigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva).  This study concluded that this treatment leads to an effective MRD reduction and has...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new targeted therapy drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.  Some background Treatments for...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Searching for patients with unresponsive chronic lymphocytic leukemia to trial an experimental treatment.

Searching for patients with unresponsive chronic lymphocytic leukemia to trial an experimental treatment.

Posted by on Aug 15, 2021 in Leukemia | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....

Read More

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years....

Read More

Acalabrutinib treatment for ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Acalabrutinib treatment for ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on May 8, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was suitable for patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) who are intolerant to ibrutinib (Imbruvica).   This study concluded that acalabrutinib was effective and well tolerated in these patients.   Some...

Read More

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting.  This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...

Read More

Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting

Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting

Posted by on Mar 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate whether venetoclax (Venclexta) is effective and well tolerated in patients with chronic lymphocytic leukemia (CLL) in a real-world setting.  This study concluded that venetoclax is safe and effective in the real-world setting in these patients.   Some background...

Read More

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).  This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...

Read More